GlassScriptPhysician profile
Mary Hinman Hockman
NPI 1811655814
$9,853.71
in general payments reported to CMS, 2019-2025
29 companies · $2,215 in 2025
The $2,215 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $829 · 2023: $2,047 · 2024: $4,205 · 2025: $2,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,200 · Travel and Lodging: $2,074 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,199.84 |
| Travel and Lodging | $2,073.54 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,800.83 | 2021-2025 | Interstim, Altaviva |
| Axonics, INC. | $1,972.35 | 2021-2024 | Axonics |
| Sumitomo Pharma America, INC. | $1,030.23 | 2023-2025 | Orgovyx, Gemtesa |
| Accord Healthcare, INC. | $482.83 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $481.06 | 2021-2025 | |
| Urogen Pharma, INC. | $347.69 | 2025 | |
| Dendreon Pharmaceuticals LLC | $332.68 | 2022-2025 | Provenge |
| Astellas Pharma US INC | $314.67 | 2022-2025 | Xtandi, Veozah, Myrbetriq |
| Abbvie INC. | $279.60 | 2022-2024 | |
| Pfizer INC. | $226.51 | 2023-2025 | |
| Teleflex LLC | $195.30 | 2023-2025 | Barrigel, Urolift |
| Myovant Sciences INC. | $175.57 | 2021-2022 | |
| Janssen Biotech, INC. | $158.28 | 2022-2025 | Carvykti, Rybrevant, Erleada |
| Merck Sharp & Dohme LLC | $157.53 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Procept Biorobotics Corporation | $149.45 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $147.97 | 2022-2024 | Lynparza |
| Urovant Sciences INC | $136.91 | 2022 | |
| Myriad Genetic Laboratories, INC. | $97.66 | 2024 | Prolaris |
| Endo USA, INC. | $85.24 | 2025 | Xiaflex, Aveed |
| 180 Medical, INC. | $73.96 | 2022-2025 | Gentlecath Glide, Cure Catheter |
| Immunitybio, INC. | $48.89 | 2025 | |
| Boston Scientific Corporation | $39.94 | 2025 | Axonics |
| Novartis Pharmaceuticals Corporation | $23.21 | 2025 | |
| Halozyme INC | $18.59 | 2023 | |
| Verity Pharmaceuticals INC. | $18.38 | 2025 | Tlando |
| Lilly USA, LLC | $15.80 | 2024 | Zepbound |
| Tolmar, INC. | $14.98 | 2024 | |
| Sun Pharmaceutical Industries INC. | $13.94 | 2023 | Yonsa |
| Acerus Pharmaceuticals Corporation | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Hockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.